<SEC-DOCUMENT>0001144204-12-014552.txt : 20120313
<SEC-HEADER>0001144204-12-014552.hdr.sgml : 20120313
<ACCEPTANCE-DATETIME>20120313151717
ACCESSION NUMBER:		0001144204-12-014552
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120307
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120313
DATE AS OF CHANGE:		20120313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollo Medical Holdings, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				87042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0131

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-25809
		FILM NUMBER:		12686971

	BUSINESS ADDRESS:	
		STREET 1:		450 NORTH BRAND BLVD.,
		STREET 2:		SUITE 600
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203
		BUSINESS PHONE:		818-507-4617

	MAIL ADDRESS:	
		STREET 1:		450 NORTH BRAND BLVD.,
		STREET 2:		SUITE 600
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v305701_8k.htm
<DESCRIPTION>8-K CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B>&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION
</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d)
OF </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF
1934 </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest
event reported): March 7, 2012</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>APOLLO MEDICAL HOLDINGS, INC.
</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified
in its charter)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; line-height: 115%; text-align: center">Delaware</TD>
    <TD STYLE="width: 5%; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 30%; line-height: 115%; text-align: center">000-25809</TD>
    <TD STYLE="width: 5%; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 30%; line-height: 115%; font-weight: bold; text-align: center"><B>20-8046599</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; text-align: center">(State or Other Jurisdiction</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%; text-align: center">(Commission File</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%; text-align: center">(I.R.S. Employer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; text-align: center">of Incorporation)</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%; text-align: center">Number)</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%; text-align: center">Identification Number)</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">700 N. Brand Blvd., Suite 450, Glendale,
CA 91203</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)
(zip code)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(818) 396-8050</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant's telephone number, including
area code)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 5.4pt; padding-left: 0; line-height: 115%"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT></TD>
    <TD STYLE="width: 97%; padding-right: 5.4pt; padding-left: 0; line-height: 115%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0; line-height: 115%"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0; line-height: 115%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0; line-height: 115%"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0; line-height: 115%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0; line-height: 115%"><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0; line-height: 115%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<HR SIZE="2" STYLE="color: Black">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.03 Creation of a Direct Financial Obligation
or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">See description of the loan from SpaGus Capital Partners,
LLC described below in Item 5.02.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3.02. Unregistered Sales of Equity Securities.
</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">The Company has issued or is committed to issue, subject
to various contingencies, shares of Common Stock in exempt private placements under Section 4(2) of the Securities Act of 1933,
as amended (the &ldquo;Securities Act&rdquo;) to Gary Augusta and his affiliated entities as described below in Item 5.02.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">The Company also issued, in connection with Mr. Schreck&rsquo;s
appointment as Chairman of the Board of Directors, warrants to purchase 1,000,000 shares of Common Stock to Edward Schreck on February
15, 2012, with such issuance (and any issuance of underlying shares of Common Stock thereunder) being made in accordance with an
exempt private placement under Section 4(2) of the Securities Act. 333,334 of the warrants have vested and are currently exercisable
and the remainder vest and become exercisable as to 333,333 of the warrants on February 15, 2013 and as to 333,333 of the warrants
on February 15, 2014. Mr. Shreck&rsquo;s warrants have an exercise price of $0.145 per share and can be exercised for ten years.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">Those equity issuances described in the preceding two
paragraphs that occurred after the Company&rsquo;s last report filed under its last periodic report but before March 7, 2012, constitute
less than 5% of the number of shares of Common Stock of the Company that are outstanding.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 5.02. Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">Effective as of March 7, 2012, Gary Augusta was elected
to the Company&rsquo;s Board of Directors. In connection with his service to the Company as a director, Mr. Augusta entered into
the Company&rsquo;s form of Director Agreement, which provides for Mr. Augusta to be a director and entitles Mr. Augusta to receive
a restricted stock grant of 400,000 shares of the Company's Common Stock. The shares will vest monthly at a rate of 1/36 per month
over a three year time period.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">In connection with Mr. Augusta&rsquo;s service as a consultant
to the Company, Mr. Augusta, through his entity, Augusta Advisors, entered into a Consulting Agreement with the Company which became
effective December 1, 2011 and which terminates on June 30, 2012. Pursuant to that agreement, various consulting services were
provided to the Company in return for $10,000 a month in cash compensation, 100,000 shares of Common Stock are being issued in
the name of Gary Augusta monthly over the term of the agreement, totaling 700,000 shares of Common Stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">As of March 7, 2012, an entity affiliated with Mr. Augusta,
SpaGus Capital Partners, LLC, had provided a $270,000 seven-month loan to the Company. The Company prepaid interest expenses of
$15,000 and closing costs of $5,000. The Company also issued 216,000 shares of Common Stock to SpaGus Capital Partners, LLC in
consideration for the loan.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7.01 Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">On March 7, 2012, the Company issued a press release
concerning some of the matters discussed above. A copy of such press release is being furnished as Exhibit 99.1 to this current
report on Form 8-K.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">The information in this Item 7.01 of this current report
on Form 8-K, together with the information in Exhibit 99.1, is being furnished and shall not be deemed &ldquo;filed&rdquo; for
the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that
Section. Such information shall not be deemed incorporated by reference into any registration statement or other document filed
with the SEC.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; line-height: 115%">99.1</TD>
    <TD STYLE="line-height: 115%">Press Release of Apollo Medical Holdings, Inc. dated March 7, 2012.</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the
Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 115%; font-weight: bold"><B>APOLLO MEDICAL HOLDINGS, INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; line-height: 115%">Dated: March 13, 2012</TD>
    <TD STYLE="width: 3%; line-height: 115%">By:&nbsp;</TD>
    <TD STYLE="width: 47%; border-bottom: black 1pt solid; line-height: 115%; font-style: italic"><I>/s/ Warren Hosseinion</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 115%">Name: Warren Hosseinion</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 115%">Title:&nbsp;&nbsp;&nbsp;&nbsp; Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>




<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v305701_ex99-1.htm
<DESCRIPTION>PRESS RELEASE OF APOLLO MEDICAL HOLDINGS, INC. DATED MARCH 7, 2012.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="image_001.gif" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<HR SIZE="1" STYLE="color: Black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">March 7, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Apollo Medical Holdings, Inc. Appoints Gary Augusta to
Board of Directors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">GLENDALE, Calif., March 7, 2012 /PRNewswire/ -- Apollo Medical
Holdings, Inc. (&quot;ApolloMed&quot;) (OTC-AMEH), a leading provider of hospitalist, critical care and multi-disciplinary care
management services to the healthcare community, today announced the appointment of Gary Augusta to its Board of Directors. &nbsp;In
addition, Mr. Augusta&rsquo;s investment firm - SpaGus Capital Partners - has agreed to provide ApolloMed with working capital.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Augusta brings more than 20 years of experience as an executive
focused on private equity, growth strategy, operations, corporate development and M&amp;A at companies ranging from start-up ventures
to Fortune 500 companies.&nbsp; He is also an experienced investor and operator of growth businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&quot;Gary brings a wide scope of experience and expertise that
will help ApolloMed earn a growing share of the $650 billion spent annually in the U.S. on inpatient hospital care,&quot; stated
Warren Hosseinion, M.D., Chief Executive Officer of Apollo Medical Holdings, Inc. &quot;His hands-on approach, business and investor
network and ability to execute will benefit us tremendously.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Augusta currently serves as President of SpaGus Ventures
LLC and SpaGus Capital Partners, growth funds that invest in life sciences and technology companies.&nbsp; He previously co-founded
and served as President and CEO of OCTANe, an innovation development corporation formed to start and fund biomedical, technology,
green tech and other types of innovative startup companies.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&quot;I look forward to working with Warren and the talented
ApolloMed team to help take the company to the next level,&quot; stated Gary Augusta.&nbsp; &quot;ApolloMed&rsquo;s unique patient-centric,
results-driven inpatient and post-discharge care delivery model positions it as a leader in this market.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Earlier in his career, Mr. Augusta was Vice President of M&amp;A
and Corporate Development at engineering and construction giant Fluor, where he focused on internal new business creation and mergers
and acquisitions.&nbsp; Prior to his tenure at Fluor, he served as a principal at global management consulting firm A.T. Kearney,
where he focused on growth strategy, operational improvement and change management assignments for clients including Prudential
Healthcare, FedEx, Wachovia and many others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other posts include serving as Executive Director of the OCTANe
Foundation for Innovation, and member of the UC Irvine CEO Roundtable, the Keck Graduate Institute Advisory Council and the UC
Irvine Advisory Boards for both the School of Engineering and the School of Information &amp; Computer Science. He serves as a
board member or advisor to several start-up companies in the biomedical and technology industries, as well as board director for
a&nbsp; publicly traded micro-cap company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Augusta resides in Southern California. He earned a BS in
Mechanical Engineering from the University of Rhode Island and a Master of Science and Management (MSM) from Georgia Tech.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">About Apollo Medical Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ApolloMed is a leading provider of integrated medical management
services that improve the quality and efficiency in inpatient hospital care. The Company&rsquo;s integrated model combines hospitalist
medicine, critical care medicine, 24-hour physician call centers, case management and transition management. Its mission is to
improve care and efficiency, while helping healthcare organizations engage in performance payments and shared accountability arrangements.
The company&rsquo;s strategy is to capitalize on the growing market for hospital-based physician and care management services.&nbsp;
There are currently 4,900 acute care hospitals in the U.S., with more than 35 million annual admissions. Total U.S. spending on
hospital care currently exceeds $650 billion and is expected to increase to $1.3 trillion by 2016. For more information, please
visit www.apollomed.net.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Media Contacts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Erik Deutsch<BR>
ExcelPR Group (for ApolloMed)<BR>
(323) 851-2300 x112<BR>
erikd@excelpr.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nidia Flores<BR>
Operations Manager<BR>
Apollo Medical Holdings, Inc.<BR>
(818) 844-3881<BR>
n.flores@apollomed.net</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.gif
M1TE&.#=A%0%@`'<``"'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"P`
M````%0%@`(?___]*4DISI=9*2DKO]_>]SN_6YO>EO=[FYMYKI=;FYO>$K=YK
ME-9SI=Y2C-Z]O;V<G+408UH0$%IK$%H08Q!K8Q`9K>89[^89K:T9[ZT9C.89
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MK5H0$"EK:\YK[UH0[UIK[Q`0[Q`0:XQK*<X0K5IKK1`0K1`0*8QK$"F]O9SO
MO5+OC)3%O5+%C)1KC%H0$`AK2LYKSEH0SEIKSA`0SA`02HQK",X0C%IKC!`0
MC!`0"(QK$`AK<WOOQ>9SA'O%WO?O:^;%:^9",6/O[W/O[S'O[[5K:Z7%[S'%
M[W/%[[6<K5I"$"F<:\Z<[UI"[UJ<[Q!"[Q!":XR<*<Y"K5J<K1!"K1!"*8R<
M$"E[SKWO[U+O[Y3%[U+%[Y2<C%I"$`B<2LZ<SEI"SEJ<SA!"SA!"2HR<",Y"
MC%J<C!!"C!!""(R<$`A[SIQ*2E*4:Z40,2EK:^^4:X00,0AK2N^UQ=Y*:UJE
MO>]*4EK_YO?___<(_P`!"!Q(L*#!@P@3*ES(L*'#AQ`C2IQ(L:+%BQ@S:MS(
ML:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-FSASZMS)LZ?/GT"#"AU*
MM*C1HTB3*EW*M*G3IU"C2IU*M:K5JUBS:MW*M:O7KV##BAU+MJS9EP32JCW+
MMJ=:`W`-J$W;MF[-N`44&%#`EX`"`O[L"D8+MT!<O7[ESAW,&"6!`I`-R#!`
MS!C<OW_3^B/0N+/(QP6,R3!6V;+>TXKI>E[-\;&^`C)"&S.&P#(QN'XS:V;-
MV^+C`Y"-Z1,=^K;EO<CG<N[-'*(QX*]?AV8A.^Y>O]@!+&_.72$!X-`AQ_\.
M7:#V[</7%VLE@$`!`@,(MFMO_SY^U[F*3_[FIX]?`>FP&5;=>;IM%IA6_CPP
M3!##/#%,,0@,!`&#0=S#X(%:&;#`A@=L*-]G_!QP`'_\_2<>:>4=I]9F='UH
M%0V5!%!))0,$(<-`-`P08P`#[..B508PT$`"#!!I@$D%B,B?/OU%!QEYIFUF
M`&3\5-F&9:I510",,O938X0`^).CC//HB&%6!A"9P)`"_/A1B"*.V.23)LH`
MV',-+-!``P+TF>>>!QCC9E/_0$!C/Y7,8R..`\PS8XV#3A5D`@(0^<>1)!D@
MX@)PDLCDDX)J]QP#`BQ0ZJE_Z)FG&J%*M64E_<C_^*5`6P[0I8Z12F6``*16
MFD"N&CW789QR-CG</P.E]9RI&S;;;*H"'(`I5`3`<FBBBP+P3XZ)>ED)L%!-
M^@>1#4PKDC$<'B"$DG+R8P"R!?U#@#X'E.KLO0L`%Q4!AI*I*)BUZDCC/F=B
ME68""#?P![@7_8-NOOG&&>)PD2ZKQ@(78ZQQL\9,A(`,L-``@<@/W'@0=O'9
MI]T#(T/P`+`?P](R+"\?5.BUBIH,`+?]]..HFP@\(+/(L-AYLG+;&3`<?W(5
M9(`Q)3;MG0'\L,`?E@L1(-Q_'0,@[I`,F/L1L@5HW"$_$1_0!K":0JS&L!AW
M^'8!$"%`PX(S5+)/)4'T_UV,#`7+4$R%"T+PSP-]\QU`$,4\D!`"$"PXX]XS
M%`YFLC#&2F,0"`06<(R0&B1##,/,D/?>?C]0<-L02SOO`D*,FZ>T`BEMJ@!\
MYBOV0+:;NB?N^79MD-8;^JG[K@@7V0##%`7F<*EPPREMP39K"O?UK0NOT#\R
M##/`]XV6"7Z--&QW>"677!+`)?=8^SV/XL\`BXN"\]AHHN+;^C=!-^OH<[8[
M&P"BRC0/^1``<?FCT3SB%P/Y&*`!16*``P00HN21*GD+D,L!B-0GA"7``;1S
MV@*29ZD$C(M4!7"1/GBE)H2!D!\FW).0=M<:@<@@3QR"&#_:`)&V;0I['=('
MS/^"\#U'><E6,YH'CRKAN($@SE:QVD<0'.6H&25J`#/H'$$00$2!'3%15QQ`
M,0@`KVW!BDR<X\RVO@<K2&$(%C.XQ`)[QD8P-LIP`S%&!RE5JA92JDA$.H`^
M'$`IA`E@7+S2AP@!Z:L6\DH`QH"70/1H2$HADH_DHA3S*,*9AP&1A@EQV`^)
M-<H4*L0?$*CC]Q@T`P%:,70"><`^=.2O[UWB>YHK4_DP=[\C,NA:-!H`#0;2
MOP$"<$R(PI5`_F&`85P"5L%<D)=ZMB.3,7.$B&0AD2ZXQT)&<%QK0E@&DW4`
M0(XK57JZ()$6L!QD;9!7X&1`!"LU)$N!,B.<X8RF[-7_.GYL4COT"E&(A""]
M.`'F<41L8R7^%C3OP<I+G'-B0C6GHV+<;4:Q*E-$8PE&&E5B&#(`V11?>0^`
MT6"6;=QHK8RH3('DJ&=+I$%(8S"C`,1*F/#:%=CJ&2T1<="$'NRI$/8D.TI-
MRQB`A&`#W/6T2G50`(JL'0LK1:H%M*%>I.H5POX)$19IIU[W"M1$H"8Q8@DT
M4&YB#X\0%8!A*`!9W$MHF9CHQ%8J<7,0$`@"&.'1*S:Q4+2$Z.4,)<`R[>.O
MA#6FSK@5@+LNQQ_>DU%CBR')8E!Q<V#24*^<*L2OTG--0NKLO)3*@'%%=5Y%
M`N<!MJ./"`92(/Y@`55])=H5_QJ25^4"R5P"4P!T-BN$$?E'DO@SHG9);%`/
M&)\P_0$O!'@OF3.H&0`0B%$Q;K&7/,HK`!!0C/OIB!%;C"S^AJDM+J74I*H,
M`AD!((,N>K2)',UE)62`+'0A[`^D6FT>'TE5_4HU843JFH8\.$."[*J##&"G
M=OC!WP1/BP"F`J<)N0J1M3R0G_FJB-(\Q>'^`#=>^NB;B'>IUWNX<A[[T.YT
MB9A,81*$`$&PZ14;N-WGOE>2`'`HHM@GH1A1\9C^F^MRW/>H85Q..\"\A'81
ML`!`KLF?O!LA4!-P``,+09T)B"KRA&14`Y?SCT+`U`CWZ%^!P%!($$S`/2N2
MS[>D1?\?.-Q09R?BFA+UQVISBB1"_%$?^&"H6BCU%GP?,(-Y9)2NR;J'YFA4
M#`5,UXJ"/5-W_1>`,8;II`+[%V?$Q$8OS6`Y_;II,<Y$`(_"E+QZ]!.IM*=9
MT#:`U4T&J@/TC%2GDJH@WYG@(SM&@"'%DQ\%,48EUT1AAK`(,YU46+.@/!&'
M5:U$!8"VB1A&QH_=[<0S&C01?PQ?[<"HL/.(080>`,:YLJ`@+XW1)8RL+<+"
M*F>,HF9+::JC[UEZ()"]*X]H@*P!<S.JVAHP[A`&<'GAEE(..#<`6,!!W++@
M:;/1T"47<.Y_[)1("E\F4LE5VC5S<BZG2<L!^%2JC(\50,/_2;F)3+D0/C\`
MTPJ\573KRE(`MEM&5[S'D2#PS)O:'`#]*C(9S=C&Q:$7B5A<SG-E%0-2%P.C
M-"+O@9\*Z]0*B8>\LS6O%%X`=3[R#R3WU51Y[=0_:L]K16IDL5N.'<P<2>(;
MHENSM0.9UVR-3I")U.&&D<3Q67%@*GYB,FU>K6LM[D:P@*)'CPP`6(S42^PN
M)K:LR2V%*KV.ZY://^@=S/)=,[648ODUP[FF@K>:JL`F``M2:VLUS?./"^C:
M(R-H<F;R$;<>EXARD(,;?QA#V6?OZM.H$YS8"&=K@W)NC&UUV8<*4$>#WL<"
M:61D2:+RC)@%NOI2JC.!&,I1/"KI_\UOI=(<"9!'GQ;(MMLXZA<_'5%>@I#7
M^C1;DY]^U0:F?R$5#L/DB5W_E7)"`G!N!.!45'5VDP)4#+!V":$6;J<7H?)[
M#5!F$N$/P5$`Q"<:&LARP_-T]P,ZPT`#"D)+\R`_=75BA&<MC051B-=SBU<0
MY*9$$*5&B35Y\?8HWR(0#F4_]P9;?.4HC=)T7F,J%]0`',ADW)1EQ"1PI.(`
M<J</Y-)!QL(D_=$&);(<$!1/9X<`!+8FN:=[V'$9<%$9:5$`T;)V8S@;E4$=
MLV$81C,\L#!]1]0X"L!GW?4H,Q=+1"0K((5CAD)1[,9SM[(/W0=T*,4CPS!T
MYA5IWM9I/?]R(-XC,`-P#_+Q#Y8%30.`1U/'0:SF*[(C=[6S`.!T2%C7==[4
M)DA#*ZK1:PE3)":'=MZT/!VQ&7^Q%WH!%[-A&:*T'=2#$`Y#1FK(`KEX&Y,1
M&C_B#Y856.)78DB$8BHF`ZTD8Y4`"R_V;?@3`T<""S8E*Y7`>-P"A!$E>?#F
M4B?64I,63#VH'?=P*-_#;Z/W!YR5-".49DJX3+O"2$Y8.Q>D/.#2:Z5%5:"H
M+1L'=B;TA1&1%K88%Y,Q&I-!``9I8/0B%Y81<9,1<?!A`+WH7"P5`-WG7(U%
M(WGX:'9T6.X'35Y"B=/52E?$.9+F19.H1C"7?8WH/[`$(V<D1J3_AE)MA$?H
M`DCX%V5I1RFM,H3WA7&3I&N/]"%48PRRD4_UE&8`-TE.5B0,B!!M-X:%\31/
M(C6AE"QXLEH.21ND$1?O81A<B6]<)#`\<F3<!4581(UZF&F92!"0A3,TUEY0
MY"C=!@`FMB.74`S+]'TV-8YK-$`MY6[?PVX#@0`>I4270(W,1$].=812QD(%
M5X#<E(\+EX2RR#OU0E4*]AT_167R`84Q5&`=@9#6(1J2$1JQ\1KY8953H@\9
M4P";41G601FF<98$(0/^XR4!<&0L,%(@&7U&Q&A;%"-M-)<UIB-WA4=Z%8EG
M1%YF1"9\HW"<1I.5<"!/)"M!T&TRH)R(_U()6D:$3F5_OF9(G5A(6R=5A\2)
M!/%[KK<`M-)_+#1.M#*/"=,F'N$/"7F14S(EXV$B=I>;N)@D&6,J;R>&[X$>
M&(D0"+`WS!<`*@9T5618@:>2C56"</DJ"R0K<,EI,C8KL31+@X=8.`-DRMDC
MRP%CKI0HE#40'IA,BLED?(1"\IAV16)Z(]0KFJDI/\4`9=8&02FD`V&&.IIE
M^22?!-EQ'^&0:>B&L'%W31(G3!(G"=HA'(*0#NF0B($<?_$X]X!S,P)2UO8$
MKB1H$O6!V`(!L,!7)EDC.A.'+%4)-,`"03-%_O.7[623YT4KYG=%,\!<VG*.
M$`4!"``Y"=58F?\(+WHD80(0D`/&GI+:9$[U!U@'`*:I3H9!/+U"*IF*//K7
M`,.!56E63U6Y9[=X'!OX)-%!(J3T-F_C+)`4)G(1<GUQJX/"+_>C1#4R.$44
M(^,Y:!KJ,PLT`+<D@^BX'0H06899(<2I0'#9;BE*>0*43#EH0\"D/V/J2C)V
M.0]D0KO63JT&3J97=@*@F4.8=O>)57^4``I&*QLT3T7B`$%93ZCI$6G8FN*Q
M<DT"J]BS,1BC3VWGI0;K:`I!;M(83&PD?0J$:"O6JX]"13B'?HQ';MBE1$9T
M1#2`L-Z&?5_B.8$Z@_"2G0)#(P$@67,U/U'F2%$YJ<HSE!(W929'2=S_Y%KU
M%VP&R)X--WO\^1'^:0`/YYI,67?_2B\BLBX!NR'&P"(@EQ8%DC7?UBCC0Z'F
M!SZ)6**N-``A.$O*!7T%<SA=]+7?LP_+&)CV4[:+=4OC8SZO0K;@$P00X$#:
M5"2@&)GRE#R7F:X1I*[:8ENNUX50=1`KE+<XJP]2%D$/J7LH0APK%VU4>%:S
MJJ7.H@_(XH#8`7*].#PQ$`2G,P-]0XV(`[J>.PS<66@@*`.($P1\,P/[,`Q[
MF2P*TC>N:SI\,PPL2Y>.1[L5`B:%(D6TFX@XQB^TNP^@FS>,0U].,W+%0W%>
M5BI"4"JPUKP#:!#/07_T9RH?%FRWTR<;HD'V_U(JJ9H0F\&4;`@9>.9A!84V
M6GH`&:-?2&,@FL$\L?4`]FN_",L>B8JG"``O3P2.$7)`]PLX#&$`]SO`!V40
M\"$#^ZLRV_4Q$*Q%Q`1;+'#`]ALA.*:*<K'!!M2E',P_7!J;\:(UQB",#R<7
M&8QK0CL;+-!F'+RX=*:;`2(=59JT<#.KS3)G\NM5@#&^^`9;,+A^7"O!$QP2
MF]M5VO$0*<P_RV0S#I'!2]R5\8(22E-W_\%AQ04G$/-;VY%/R9+$)D%H6[M1
MW6$4H$&@3%)09O-;+6R5*X%`-P529;P042S%CE'%)-(I2KO%@O2@-"%+SDFB
M7U''6:$U+%!<Q,+'G8-Z$X0V?4-\Q%5!R%P!I;-1)?T1&B)L$V(<MZ\XQT@A
M+URZ&SO!73%`#\50#(CJR:K</'\1'WP&R:L<R]LCR[1<R[9\R[B<R[J\R[S<
MR[[\R\`<S,(\S,1<S,9\S,B<S,J\S,S<S,[\S-`<S=(\S=1<S=9\S=B<S=J\
,S=S<S=[\S481$``[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
